The company's anti-infective drug Cefminox Sodium for Injection was issued the “Notification of approval of drug supplement application” (No. 2023B03576 and 2023B03577) by NMPA, indicating the drug passed the consistency evaluation of generic drugs.

Cefminox Sodium for Injection is an anti-infective drug, it shows strong affinity for penicillin-binding proteins as β-lactam antibiotics, which not only inhibits the synthesis of the cell wall, but also binds to peptidoglycan and inhibits the binding of peptidoglycan to lipoproteins in order to promote lysis of the bacteria, and displays a strong bactericidal power in a short period of time. The drug is indicated for septicemia, tonsillitis (including peri-tonsillar abscesses), acute bronchitis, pneumonia, lung abscess, chronic respiratory tract pathology secondary infections, cystitis, pyelonephritis, peritonitis, cholecystitis, cholangitis, intrauterine infections, adnexitis, parathyroiditis infected by cefminox susceptible microorganisms such as Streptococcus spp, Streptococcus pneumoniae, Escherichia coli, Klebsiella, Aspergillus, Morganella, Prophidium, Haemophilus influenzae, Anaplasticus, Prevotella.The approval of consistency evaluation of the Company's cefminox sodium for injection is not only conducive to enhancing the market competitiveness and providing strong support for the expansion of anti-infectives product market, but also an important achievement of the Company's products in the field of anti-infectives, which will have a positive impact on the Company's operation.